Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 24

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 24
---
 vote is very important. Whether or not you plan to participate at the Meeting, please submit your proxy card without delay. Proxy cards must be submitted no later than the time appointed for the commencement of the Meeting or adjourned or postponed Meeting. Shareholders may revoke proxies at any time before they are voted at the Meeting. Voting by proxy will not prevent a shareholder from attending the Meeting in person if such shareholder subsequently chooses to participate in the Meeting. We encourage you to read this proxy statement/prospectus carefully. In particular, you should review the matters discussed under the caption “ Risk Factors ” beginning on page 72. The Denali Board obtained an opinion from CB Capital that the Business Combination was fair, from a financial point of view. See the section titled “ Proposal 1 — The Business Combination Proposal — Opinion of CB Capital ” and the opinion attached as Annex Hto this proxy statement/prospectus. xiii

After careful consideration of the terms and conditions of the Merger Agreement, the Denali Board has determined that the Business Combination and the transactions contemplated thereby are fair to, and in the best interests of, Denali and its shareholders. The Denali Board recommends that Denali’s shareholders vote “FOR” the approval of each of the proposals described in this proxy statement/prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued in the Business Combination or otherwise, or passed upon the adequacy or accuracy of this proxy statement/prospectus. Any representation to the contrary is a criminal offense. This proxy statement/prospectus is dated , 2025, and is first being mailed to shareholders of Denali on or about , 2025.

| /s/ Lei Huang                                                                      |
| Lei Huang Chief Executive Officer Denali Capital Acquisition Corp.          , 2025 |

xiv

DENALI CAPITAL ACQUISITION CORP. 437 Madison Avenue, 27th Floor New York, NY 10022 Telephone: 646-978-5180 NOTICE OF EXTRAORDINARY GENERAL MEETING OF DENALI CAPITAL ACQUISITION CORP. To Be Held on , 2025 To Denali Capital Acquisition Corp. Shareholders: NOTICE IS HEREBY GIVEN that an extraordinary general meeting of the shareholders (the “Meeting”) of Denali Capital Acquisition Corp. (“Denali,” “we,” “our,” or “us”), will be held at , Eastern time,